M1 Kliniken AG
- WKN: A0STSQ
- ISIN: DE000A0STSQ8
- Land: Deutschland
Nachricht vom 15.12.2020 | 15:10
M1 Kliniken AG disposes subsidiary 'M1 Aesthetics GmbH' to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG AG:
DGAP-News: M1 Kliniken AG
/ Key word(s): Investment/Disposal
M1 Kliniken AG disposes subsidiary "M1 Aesthetics GmbH" to HAEMATO AG - Transfer of the holding of the company within the scope of a capital increase in kind of HAEMATO AG
With this transaction, M1 Kliniken AG is pursuing its strategy to focus the company on the beauty treatment business, which began in mid-2020, while the trading and product business will be bundled in the subsidiary HAEMATO AG. In addition the combination of the product and trading activities of M1 Aesthetics under the umbrella of HAEMATO AG, it is the long-term strategy of the M1 Kliniken Group to increase the vertical integration of its own activities. To this end, it is intended to establish a selection of high-quality treatment products (hyaluronic acid and botulinum toxin) as a "M1 private label" in the medium term and thereby strengthen the earning power, especially in the entry-level price segment.
Dr. Walter von Horstig, Member of the Board of Directors of M1 Kliniken AG, comments on the transaction as follows: "The implementation of our strategy "Quality does not have to be expensive" repeatedly calls for the development of value creation potential. Our long-term private label strategy will be an important element in this respect in the future. Favourable prices mean a larger market with simultaneously rising margins from the various stages of the value chain. HAEMATO AG's established development platform is an ideal starting point for this and will help us to implement the strategy quickly and securely".
M1 Aesthetics GmbH was valued on the basis of an IDW-S1 expert opinion with an enterprise value of a good € 58 million. The new HAEMATO shares were issued at a reference price of €23.55 per share, which corresponds to the volume-weighted average price of HAEMATO AG in the Xetra trading system in the period from 27.11.2020 to 9.12.2020.
In 2019 M1 Aesthetics GmbH reported sales of about 51 million Euro and an EBIT of almost 7 million Euro. For 2020, M1 Aesthetics GmbH is expecting sales of a good EUR 30 million and an EBIT of approximately EUR 4 million - also due to corona effects, among other things. A further increase in earnings is expected in the coming years.
About M1 Kliniken AG
M1 Kliniken AG
Dr. Walter von Horstig, Management Board
Grünauer Straße 5
T: +49 (0)30 347 47 44 14
|Company:||M1 Kliniken AG|
|Grünauer Straße 5|
|Phone:||+49 (0)30 347 47 44 14|
|Fax:||+49 (0)30 347 47 44 17|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1155182|
|End of News||DGAP News Service|
M1 Kliniken AG continues successful developmen ...
M1 Kliniken AG announces financials for Q3-202 ...
M1 Kliniken AG continues growth course
M1 Kliniken AG publishes figures for the 1st h ...
M1 Kliniken AG successfully held its Annual Ge ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 18:19 Musterdepot-Titel BHP: Es geht voran
03. Dezember 19:02 Dow Jones: Es hört nicht auf ...
03. Dezember 19:50 Commerzbank und Deutsche Bank: "Bitte keine großzügige ...
03. Dezember 20:20 Apple unter Druck – aber die Lage hellt sich langsam auf
03. Dezember 21:33 Schlussglocke: Dow Jones schließt schwache Woche mit weiterem Minus ab
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021